Refractory Clinical Trial
Official title:
Clinical Study of CD19/CD20 Bispecific Nanobody-derived CAR-T Cells in Refractroy/Relasped B Cell Lymphoma
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may reduce the recurrence rate after treatment. This study was to evaluate the efficacy and safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
Not yet recruiting |
NCT06424301 -
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
|
Early Phase 1 | |
Active, not recruiting |
NCT02280993 -
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
|
Phase 1 | |
Completed |
NCT00752518 -
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03085173 -
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03179930 -
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
|
Phase 2 | |
Recruiting |
NCT03275493 -
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05153330 -
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
|
Phase 1 | |
Recruiting |
NCT03881774 -
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT02407275 -
Rhinosinusites Chroniques
|
N/A | |
Recruiting |
NCT05911321 -
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
|
Phase 2 | |
Not yet recruiting |
NCT04599452 -
NK Cell Therapy Recurrent/Refractory Elderly AML
|
Phase 1/Phase 2 | |
Recruiting |
NCT06090864 -
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06265545 -
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
|
N/A |